Unscripted with @jrichlive ft. Tom Lemberg (Curebase)

TL;DR

Curebase CEO Tom Lemberg discusses the company's mission to transform the clinical trial industry by directly connecting patients to trials, the impact of COVID-19, and the future of decentralized trials.

Transcript

how are you really good good good i think last time i saw you i was wearing this shirt and you were wearing that shirt or something similar so we have met we have met once in person um in i think san mateo and it's been zoomed for the rest of our relationship so so so i think it'd be fun to give people a little bit of your background uh you know wh... Read More

Key Insights

• 😒 The clinical trial industry is undergoing a transformation, with a shift towards patient-centric trials and the use of digital technologies.
• 👻 COVID-19 has accelerated the adoption of decentralized trials, allowing patients to participate from the comfort of their homes.
• 🥺 Curebase is leading the charge in revolutionizing the industry by directly connecting patients to trials and leveraging technology to streamline the process.

Questions & Answers

Q: How has COVID-19 impacted the adoption of decentralized clinical trials?

COVID-19 has accelerated the shift towards decentralized trials, as travel restrictions and safety concerns have forced the industry to embrace remote patient engagement and digital technologies.

Q: What are the challenges of conducting clinical trials for rare diseases?

Conducting trials for rare diseases is challenging due to the small patient population and geographic limitations. Decentralized trials can overcome these challenges by reaching patients directly where they live and engaging them through telemedicine.

Q: How is Curebase leveraging real-world health records in clinical trials?

Curebase is investing in utilizing electronic health records (EHRs) to drive phase three FDA-regulated research. By tapping into real-world data, they aim to enhance the power and effectiveness of clinical trials.

Q: What milestones can we expect from Curebase in the near future?

Curebase plans to launch its first rare disease studies and showcase the success of decentralized trials. They also aim to expand globally and demonstrate the impact of tapping into EHRs in clinical research.

Summary & Key Takeaways

• Tom Lemberg grew up in Michigan and studied computer science at Harvard before becoming deeply invested in applying his technology background to healthcare and medicine.

• He worked in various healthcare technology roles and founded Curebase to use technology to connect patients to clinical trials directly.

• Curebase has experienced significant growth, secured major enterprise clients, and is expanding globally.